Fingolimod hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for fingolimod hydrochloride and what is the scope of patent protection?
Fingolimod hydrochloride
is the generic ingredient in two branded drugs marketed by Accord Hlthcare, Alkem Labs Ltd, Apotex, Aurobindo Pharma Ltd, Biocon Ltd, Bionpharma, Chartwell Rx, Dr Reddys, Ezra Ventures, Glenmark Pharms Ltd, Hec Pharm Co Ltd, Hetero Labs Ltd V, Mylan, Prinston Inc, Sun Pharm, Teva Pharms Usa, Zydus Pharms, and Novartis, and is included in nineteen NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Fingolimod hydrochloride has two hundred and forty-six patent family members in fifty countries.
There are twenty drug master file entries for fingolimod hydrochloride. Twenty suppliers are listed for this compound.
Summary for fingolimod hydrochloride
International Patents: | 246 |
US Patents: | 4 |
Tradenames: | 2 |
Applicants: | 18 |
NDAs: | 19 |
Drug Master File Entries: | 20 |
Finished Product Suppliers / Packagers: | 20 |
Raw Ingredient (Bulk) Api Vendors: | 139 |
Clinical Trials: | 75 |
Patent Applications: | 739 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for fingolimod hydrochloride |
What excipients (inactive ingredients) are in fingolimod hydrochloride? | fingolimod hydrochloride excipients list |
DailyMed Link: | fingolimod hydrochloride at DailyMed |
Recent Clinical Trials for fingolimod hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tang-Du Hospital | Phase 1/Phase 2 |
The Methodist Hospital Research Institute | Phase 2 |
General Hospital of Shenyang Military Region | Phase 4 |
Pharmacology for fingolimod hydrochloride
Drug Class | Sphingosine 1-phosphate Receptor Modulator |
Mechanism of Action | Sphingosine 1-Phosphate Receptor Modulators |
Medical Subject Heading (MeSH) Categories for fingolimod hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for fingolimod hydrochloride
Paragraph IV (Patent) Challenges for FINGOLIMOD HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
GILENYA | Capsules | fingolimod hydrochloride | 0.25 mg | 022527 | 1 | 2018-07-19 |
GILENYA | Capsules | fingolimod hydrochloride | 0.5 mg | 022527 | 19 | 2014-09-22 |
US Patents and Regulatory Information for fingolimod hydrochloride
Expired US Patents for fingolimod hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | GILENYA | fingolimod hydrochloride | CAPSULE;ORAL | 022527-002 | May 11, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | GILENYA | fingolimod hydrochloride | CAPSULE;ORAL | 022527-001 | Sep 21, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | GILENYA | fingolimod hydrochloride | CAPSULE;ORAL | 022527-001 | Sep 21, 2010 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for fingolimod hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2698154 | Modulateurs du récepteur S1P pour traiter la sclérose en plaques (S1P receptor modulators for treating multiple sclerosis) | ⤷ Sign Up |
Poland | 1613288 | ⤷ Sign Up | |
Australia | 2013200356 | S1P receptor modulators for treating multiple sclerosis | ⤷ Sign Up |
European Patent Office | 2037906 | MODULATEURS DU RÉCEPTEUR DE LA S1P DESTINÉS AU TRAITEMENT DE LA SCLÉROSE EN PLAQUES (S1P RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS) | ⤷ Sign Up |
European Patent Office | 2694037 | FORMULATIONS COMPRENANT 2-AMINO-2-[2-(4-OCTYLPHENYL)ETHYL]PROPANE-1,3-DIOL (FORMULATIONS COMPRISING 2-AMINO-2-[2-(4-OCTYLPHENYL)ETHYL]PROPANE-1,3-DIOL) | ⤷ Sign Up |
Ukraine | 112857 | ПРЕПАРАТ, ЩО МІСТИТЬ 2-АМІНО-2-[2-(4-ОКТИЛФЕНІЛ)ЕТИЛ]ПРОПАН-1,3-ДІОЛ | ⤷ Sign Up |
Norway | 329332 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for fingolimod hydrochloride
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1613288 | SPC/GB11/045 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317 |
1613288 | C01613288/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: FINGOLOMOD; REGISTRATION NO/DATE: SWISSMEDIC 60916 20110103 |
0627406 | 1190015-6 | Sweden | ⤷ Sign Up | PRODUCT NAME: FINGOLIMOD; REG. NO/DATE: EU/1/11/677/001-04 20110317 |
1613288 | 1190025-5 | Sweden | ⤷ Sign Up | PERIOD OF VALIDITY (FROM - UNTIL): 20240407 - 20260321 |
1613288 | C300497 | Netherlands | ⤷ Sign Up | PRODUCT NAME: FINGOLIMOD ALSMEDE FARMACEUTISCH AANVAARDBARE AFGELEIDEN DAARVAN, IN HET BIJZONDER FINGOLIMOD HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/677/001-004 20110317 |
1613288 | 2011C/030 | Belgium | ⤷ Sign Up | PRODUCT NAME: FINGOLIMOD; AUTHORISATION NUMBER AND DATE: EU/1/11/677/001 20110322 |
0627406 | C300488 | Netherlands | ⤷ Sign Up | PRODUCT NAME: FINGOLIMOD, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER FINGOLIMOD HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/677/001-004 20110317 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.